| ||
| FDA to Take a Second Look at Breast Cancer Drug Fox News The US Food and Drug Administration (FDA) on Friday confirmed it would give drug-maker Genentech a second chance to keep Avastin on the market as a treatment for breast cancer. The FDA announced in December that it was pulling the cancer drug's ... See all stories on this topic » | ||
| Blocking of Enzyme Prevents Cancer Metastasis Yahoo! News This prevented breast cancer from metastasizing to other tissues. These findings are important in terms of drug development, but they also play an important role in developing a test with the potential of being able to predict how likely cancer is to ... See all stories on this topic » | ||
| £3m of cancer drug money still unspent Oxford Mail Janet Hodges, from Carterton, is one of the lucky few who was given breast cancer drug Lapatinib thanks to the fund Mrs Hodges was diagnosed with breast cancer in 2005 and has since learned it has spread to her brain. After treatment that included a ... See all stories on this topic » | ||
| ||
| Husband who gave wife lethal injection says he was following 'doctor's orders.' Montreal Gazette Barbara Jollimore-Bolton, 59, was suffering from advanced breast cancer. While it seemed initially that Bolton had admitted to purposely ending his wife's life without her consent, he now says he was simply following doctors' instructions when he ... See all stories on this topic » | ||
| Analysis of tissue textures could aid cancer treatment The Engineer The software analyses computed tomography (CT) images from colorectal, lung, renal, prostate and esophageal cancers, as well as breast cancer mammograms. It derives 'textures' from the scans that give information about tissue characteristics and ... See all stories on this topic » | ||
| Enlyton to Develop ViroMed mAb for Cancer Detection and Drug Delivery Genetic Engineering News The company says that its main areas of focus are DNA/protein-based biopharmaceuticals and phytotherapeutics (botanical drugs/nutraceuticals). ViroMed has five developmental candidates targeting cardiovascular disease, cancer, and immune-related ... See all stories on this topic » | ||
| Health Care: A Fit Forecast AdvisorOne Overall, we continue to think Roche's aggressive cost cutting, strong pipeline, and emerging market potential will provide a buffer from pressure due to Avastin in breast cancer, reform costs, and in the long run, bio-similar competition. ... See all stories on this topic » | ||
| Gilead Bets $600M on Cancer, Genentech Gets a Hearing, Jennerex Shows Early ... Xconomy The South San Francisco-based unit of Roche said this week that the FDA has agreed to let the company make its case on June 28 & 29 for why the drug should continue to be cleared for sale as a treatment for breast cancer, after the FDA said in December ... See all stories on this topic » | ||
| ||
| Another reason dogs are man's best friend Winnipeg Free Press A study published in the Integrative Cancer Therapies shows dogs can also distinguish between patients who have early and late-stage lung and breast cancer. So what do dogs have that cancer specialists don't? A dog's nose contains 220 million cells ... See all stories on this topic » | ||
| Cancer services offers free screenings WNYT Screenings may include mammograms, breast and pelvic exams, pap tests for women 40+, and colorectal cancer screening kits for men and women 50+. The screenings are from 10 am to 2 pm in the Bassett Mobile Coach at St. Johnsville Kinney Drugs. See all stories on this topic » | ||
| Multiple Childbirth Linked To Rare But Aggressive 'Triple-Negative' Breast Cancer Medical News Today (press release) ... who remain childless have about a 40 percent higher risk of estrogen-receptor-positive breast cancer - the most common form of the disease, which can be treated with estrogen-blocking drugs - as compared to those who have one or more offspring. ... See all stories on this topic » | ||
| The More Times a Woman Gives Birth, the Higher Her Risk of Rare but Aggressive ... SunHerald.com (press release) 25, 2011 -- /PRNewswire/ -- Full-term pregnancy has long been associated with a reduced risk of breast cancer, but a new study finds that the more times a woman gives birth, the higher her risk of "triple-negative" breast cancer, a relatively uncommon ... See all stories on this topic » | ||
| Piper Alderman > Health andLife Sciences Update-Legal Rx - February 2011 Linex Legal (press release) (registration) The case centres on patents relating to the BRCA1 gene, which is linked to an increased risk of breast and ovarian cancer. The basis of the case is that the patent on the BRCA1 gene held by US-based Myriad Genetics Inc and Melbourne-based Genetic ... See all stories on this topic » |
| ||
| Common Chemotherapy Drugs--Vincristine Vincristine is also given to patients with lymphoma, both Hodgkins and non- Hodgkins, and used against a type of kidney cancer called Wilm's tumor. Patients with breast cancer or small-cell lung cancer are sometimes prescribed ... Suite101: Chemotherapy Articles - http://www.suite101.com/chemotherapy | ||
| Another weeks worth of healthcare marketing news | Pharma Marketer By Richard Meyer Even before U.S. regulators in December moved to revoke the drug's conditional approval for treating breast cancer, Kent Osborne, a Texas oncologist, said in an interview that he was reducing use of the drug, citing its "huge" costs, ... Pharma Marketer - http://www.pharma-marketer.com/ |
| ||
| Breast Cancer Drugs The mind is fascinating bundle of the opposite sex. But while a hidden source of cancer killer of women in the thousands each year. [Breast Cancer Drugs] ... breastcancerdrugs.org/ | ||
| FDA grants hearing to Genentech over breast cancer drug | The ... The FDA letter sent to the lawyers of the company on Wednesday allows two day s of public hearing to the company. Genentech gets another chance Genentech ... www.themoneytimes.com/.../fda-grants-hearing-genentech-ov... | ||
| UPDATE 1-Elan, Celgene settle suit over breast cancer drug | Reuters Settle patent infringement suit over Abraxane * Celgene to pay Elan one-time fee of $78 million NEW YORK, Feb 24 (Reuters) - Elan Corp Plc andCelgene Corp ... www.reuters.com/.../celgene-elan-idUSN247511220110225 | ||
| Herceptin May Boost Long-Term Survival After Aggressive Breast ... 24 (HealthDay News) -- The cancer drug Herceptin produces significantly longer disease-free survival in women with an aggressive type of early-stage breast ... article.wn.com/.../Herceptin_May_Boost_LongTerm_Survival... | ||
| Popular Bone Drugs Linked to Reduced Colon Cancer Risk 15 (HealthDay News) -- People who take drugs called bisphosphonates to prevent ... "We also found a similar effect last year with risk of breast cancer, ... health.yahoo.net/.../popularbonedrugslinkedtoreducedcolonca... |
Tip: Use quotes ("like this") around a set of words in your query to match them exactly. Learn more.
Remove this alert.
Create another alert.
Manage your alerts.
No comments:
Post a Comment